Minerva Neurosciences, Inc. (NERV) Discusses Roluperidone as a Potential First Treatment for Negative Symptoms of Schizophrenia Transcript
Minerva Stock Rises After Securing $200M for Schizophrenia Drug Trial - Minerva Neurosciences (NASDAQ:NERV)